These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 38502075)
1. Stroke Risk After COVID-19 Bivalent Vaccination Among US Older Adults. Lu Y; Matuska K; Nadimpalli G; Ma Y; Duma N; Zhang HT; Chiang Y; Lyu H; Chillarige Y; Kelman JA; Forshee RA; Anderson SA JAMA; 2024 Mar; 331(11):938-950. PubMed ID: 38502075 [TBL] [Abstract][Full Text] [Related]
2. Ischemic Stroke After Bivalent COVID-19 Vaccination: Self-Controlled Case Series Study. Xu S; Sy LS; Hong V; Holmquist KJ; Qian L; Farrington P; Bruxvoort KJ; Klein NP; Fireman B; Han B; Lewin BJ JMIR Public Health Surveill; 2024 Jun; 10():e53807. PubMed ID: 38916940 [TBL] [Abstract][Full Text] [Related]
3. Estimated Effectiveness of Coadministration of the BNT162b2 BA.4/5 COVID-19 Vaccine With Influenza Vaccine. McGrath LJ; Malhotra D; Miles AC; Welch VL; Di Fusco M; Surinach A; Barthel A; Alfred T; Jodar L; McLaughlin JM JAMA Netw Open; 2023 Nov; 6(11):e2342151. PubMed ID: 37938846 [TBL] [Abstract][Full Text] [Related]
4. Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines. Kelly JD; Leonard S; Hoggatt KJ; Boscardin WJ; Lum EN; Moss-Vazquez TA; Andino R; Wong JK; Byers A; Bravata DM; Tien PC; Keyhani S JAMA; 2022 Oct; 328(14):1427-1437. PubMed ID: 36156706 [TBL] [Abstract][Full Text] [Related]
5. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022. Hause AM; Marquez P; Zhang B; Myers TR; Gee J; Su JR; Blanc PG; Thomas A; Thompson D; Shimabukuro TT; Shay DK MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(44):1401-1406. PubMed ID: 36327162 [TBL] [Abstract][Full Text] [Related]
6. BA.1 Bivalent COVID-19 Vaccine Use and Stroke in England. Andrews N; Stowe J; Miller E; Ramsay M JAMA; 2023 Jul; 330(2):184-185. PubMed ID: 37318811 [TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lazarus R; Baos S; Cappel-Porter H; Carson-Stevens A; Clout M; Culliford L; Emmett SR; Garstang J; Gbadamoshi L; Hallis B; Harris RA; Hutton D; Jacobsen N; Joyce K; Kaminski R; Libri V; Middleditch A; McCullagh L; Moran E; Phillipson A; Price E; Ryan J; Thirard R; Todd R; Snape MD; Tucker D; Williams RL; Nguyen-Van-Tam JS; Finn A; Rogers CA; Lancet; 2021 Dec; 398(10318):2277-2287. PubMed ID: 34774197 [TBL] [Abstract][Full Text] [Related]
8. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023. Hause AM; Marquez P; Zhang B; Su JR; Myers TR; Gee J; Panchanathan SS; Thompson D; Shimabukuro TT; Shay DK MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(2):39-43. PubMed ID: 36634021 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study. Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148 [TBL] [Abstract][Full Text] [Related]
10. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. Oster ME; Shay DK; Su JR; Gee J; Creech CB; Broder KR; Edwards K; Soslow JH; Dendy JM; Schlaudecker E; Lang SM; Barnett ED; Ruberg FL; Smith MJ; Campbell MJ; Lopes RD; Sperling LS; Baumblatt JA; Thompson DL; Marquez PL; Strid P; Woo J; Pugsley R; Reagan-Steiner S; DeStefano F; Shimabukuro TT JAMA; 2022 Jan; 327(4):331-340. PubMed ID: 35076665 [TBL] [Abstract][Full Text] [Related]
11. Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination. Beatty AL; Peyser ND; Butcher XE; Cocohoba JM; Lin F; Olgin JE; Pletcher MJ; Marcus GM JAMA Netw Open; 2021 Dec; 4(12):e2140364. PubMed ID: 34935921 [TBL] [Abstract][Full Text] [Related]
12. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States. Abara WE; Gee J; Marquez P; Woo J; Myers TR; DeSantis A; Baumblatt JAG; Woo EJ; Thompson D; Nair N; Su JR; Shimabukuro TT; Shay DK JAMA Netw Open; 2023 Feb; 6(2):e2253845. PubMed ID: 36723942 [TBL] [Abstract][Full Text] [Related]
13. Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans. Dickerman BA; Madenci AL; Gerlovin H; Kurgansky KE; Wise JK; Figueroa Muñiz MJ; Ferolito BR; Gagnon DR; Gaziano JM; Cho K; Casas JP; Hernán MA JAMA Intern Med; 2022 Jul; 182(7):739-746. PubMed ID: 35696161 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S. Shoaibi A; Lloyd PC; Wong HL; Clarke TC; Chillarige Y; Do R; Hu M; Jiao Y; Kwist A; Lindaas A; Matuska K; McEvoy R; Ondari M; Parulekar S; Shi X; Wang J; Lu Y; Obidi J; Zhou CK; Kelman JA; Forshee RA; Anderson SA Vaccine; 2023 Jul; 41(32):4666-4678. PubMed ID: 37344261 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial. Tan NH; Geers D; Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Bogers S; van Dijk LLA; Gommers L; van Leeuwen LPM; Boerma A; Nijhof SH; van Dort KA; Koopmans MPG; Dalm VASH; Lafeber M; Kootstra NA; Huckriede ALW; van Baarle D; Zaeck LM; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM; Lancet Infect Dis; 2023 Aug; 23(8):901-913. PubMed ID: 37088096 [TBL] [Abstract][Full Text] [Related]
16. Comparative Risks of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Older US Adults. Harris DA; Hayes KN; Zullo AR; Mor V; Chachlani P; Deng Y; McCarthy EP; Djibo DA; McMahill-Walraven CN; Gravenstein S JAMA Netw Open; 2023 Aug; 6(8):e2326852. PubMed ID: 37531110 [TBL] [Abstract][Full Text] [Related]
17. Herpes Zoster Vaccine Live and Risk of Stroke Among Medicare Beneficiaries: A Population-Based Cohort Study. Yang Q; Chang A; Tong X; Merritt R Stroke; 2021 May; 52(5):1712-1721. PubMed ID: 33874749 [TBL] [Abstract][Full Text] [Related]
18. Surveillance for Guillain-Barré syndrome after 2015-2016 and 2016-2017 influenza vaccination of Medicare beneficiaries. Arya DP; Said MA; Izurieta HS; Perez-Vilar S; Zinderman C; Wernecke M; Alexander M; White T; Su IH; Lufkin B; MaCurdy T; Kelman J; Forshee R Vaccine; 2019 Oct; 37(43):6543-6549. PubMed ID: 31515146 [TBL] [Abstract][Full Text] [Related]
19. Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study. Yamin D; Yechezkel M; Arbel R; Beckenstein T; Sergienko R; Duskin-Bitan H; Yaron S; Peretz A; Netzer D; Shmueli E Lancet Infect Dis; 2023 Oct; 23(10):1130-1142. PubMed ID: 37352878 [TBL] [Abstract][Full Text] [Related]
20. Risk for Myocardial Infarction, Stroke, and Pulmonary Embolism Following COVID-19 Vaccines in Adults Younger Than 75 Years in France. Botton J; Jabagi MJ; Bertrand M; Baricault B; Drouin J; Le Vu S; Weill A; Farrington P; Zureik M; Dray-Spira R Ann Intern Med; 2022 Sep; 175(9):1250-1257. PubMed ID: 35994748 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]